Margarida Azevedo, MSc,  —

The Cystic Fibrosis Foundation has awarded up to $5 million to Armata Pharmaceuticals to advance its potential treatment AP-PA02 — a phage therapy against multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients — into a Phase 1b/2 clinical trial. Phage therapy harnesses the properties of …

AB569 is safe and effective at killing bacteria resistant to traditional antibiotics, in particular Pseudomonas aeruginosa (P. aeruginosa), an important disease-exacerbating microbe in cystic fibrosis (CF), a study showed. The study, “AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria,” was published in the journal…

A new non-invasive tool, called XV technology, allows professionals to visualize airflow in a living lungs and could help in the diagnosis, monitoring, and treatment of cystic fibrosis (CF) and other respiratory lung diseases, scientists report. The technology was developed by researchers at Monash University, and has been patented by the…

Vertex Pharmaceuticals recently gave an update on its Phase 3 development program, which consists of four studies, on the investigational compound VX-661 in combination with Kalydeco (ivacaftor) as a treatment of patients with cystic fibrosis (CF). The company plans to terminate one study, which is investigating VX-661 plus ivacaftor in people with one copy of…

ProMetic Life Sciences Inc. recently announced that Health Canada has approved the initiation of a clinical trial assessing the company’s anti-fibrotic lead drug candidate, PBI-4050, in patients with cystic fibrosis (CF). The Phase 2 study, which is expected to begin in shortly, aims to evaluate the drug’s effects on pancreatic and lung function…

Researchers at the Queen’s University Belfast developed a new compound that may change how lung ailments in cystic fibrosis (CF) are treated. The potential medicine was shown in an early study to improve airway hydration and increase mucus clearance, results that suggest a mechanism to potentially delay or prevent lung disease independently of the…

International Biophysics Corporation recently announced the publication of new data regarding the effectiveness of its AffloVest airway clearance technology in patients with cystic fibrosis. The paper, “Lung function improvement with AffloVest® HFCWO use: a clinician’s perspective on PFT score data from 12 patients with cystic fibrosis,” was published on the…

People whose cystic fibrosis was detected through screening programs for newborns were found to have better growth throughout puberty and superior adult height, compared to those whose CF was diagnosed after they began exhibiting symptoms, researchers at the University of Wisconsin–Madison reported. The study, based on analyzed data from the Wisconsin Randomized Clinical Trial, “Pubertal Height…

Researchers at the University of Pittsburgh Center for Vaccine Research (CVR) have developed an engineered antimicrobial peptide effective against co-infection by bacterial microfilm and a virus, and as such is a possible new therapeutic agent against chronic and antibiotic-resistant infections. Importantly, the potential drug was tested against Pseudomonas aeruginosa, one of the primary and more dangerous…

The Cystic Fibrosis Foundation, a leading supporter of research funding for new cystic fibrosis (CF) treatments with the goal of finding a cure, announced the appointment of Marc Ginsky as its new executive vice president and chief operating officer. Ginsky will report to the organization’s president and chief executive officer, Dr.